Diflucan 150 mg (Fluconazole) and Fesoterodine: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A4 inhibition may increase the active fesoterodine metabolite, with extra concern in renal or hepatic impairment.
Clinical significance and safety
Diflucan 150 mg (Fluconazole) and Fesoterodine: The clinician should check kidney and liver function before concurrent use. Routine adjustment may not be needed with normal organ function, while impairment can impose restrictions; severe renal or moderate hepatic impairment may require avoidance. Report inability to pass urine or severe constipation. Do not apply strong-inhibitor rules indiscriminately to moderate inhibitors.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.